Man Dana Emilia, Andor Minodora, Buda Valentina, Kundnani Nilima Rajpal, Duda-Seiman Daniel Marius, Craciun Laura Maria, Neagu Marioara Nicula, Carlogea Iulia-Stefania, Dragan Simona-Ruxanda
Department VI-Cardiology, University Clinic of Internal Medicine and Ambulatory Care, Prevention and Cardiovascular Recovery, "Victor Babes" University of Medicine and Pharmacy, 3000041 Timisoara, Romania.
Research Centre of Timisoara Institute of Cardiovascular Diseases, "Victor Babes" University of Medicine and Pharmacy, 3000041 Timisoara, Romania.
J Pers Med. 2024 Aug 28;14(9):911. doi: 10.3390/jpm14090911.
The COVID-19 pandemic has caused severe health issues worldwide and contributed to huge financial losses. Key comorbidities linked to an increased risk of severe COVID-19 and higher mortality rates include cardio-metabolic disorders such as type 1 and type 2 diabetes mellitus (T1DM and T2DM), atherosclerotic cardiovascular disease, chronic kidney disease, hypertension, heart failure, and obesity. The persistence of symptoms even after the acute phase is over is termed long COVID-19 syndrome. This study aimed to evaluate the relationship between long COVID-19 syndrome and the development of insulin resistance in previously non-diabetic patients. A prospective observational study was performed on 143 non-diabetic patients who had tested positive for SARS-CoV-2 infection by a PCR test and were hospitalized in our hospital between January 2020 and December 2022. The clinical and para-clinical data at 0, 4, and 12 months of hospital admission for post-COVID-19 infection follow-up was collected and labeled as t0, t4, and t12. Blood glucose, insulin, and C-peptide levels were measured at the beginning and further at 2, 5, 10, and 30 min after the intravenous arginine stimulation test. Similarly, BMI was calculated, and hs-CRP and ESR levels were noted. The results obtained were statistically analyzed. More than one-third (30.7%) of the included patients developed long COVID-19 syndrome. It was found that 75% of patients with long COVID-19 hospitalized in our clinic developed diabetes within a year of acute infection with COVID-19; therefore, it can be said that the presence of long COVID-19 is a major risk for an altered metabolic status, which can cause diabetes. When comparing the glycemia levels (106 mg/dL) with the BMI at t0, t4, and t12 time intervals, the p-values were found to be 0.214, 0.042, and 0.058, respectively. Almost 62% of the patients having BMI > 30 kg/m were found to have an increase in blood glucose levels at 1 year. Similarly, insulin resistance was noted during this interval. A negative correlation of 0.40 for hsCRP and 0.38 for ESR was noted when compared with acute infection with COVID-19. The association between long COVID-19 and insulin resistance highlights the varied and widespread impacts of SARS-CoV-2 infection. Addressing the complexities of long COVID-19 requires a holistic strategy that encompasses both respiratory and metabolic considerations, which is crucial for enhancing the well-being of those enduring this persistent condition.
新冠疫情在全球范围内引发了严重的健康问题,并造成了巨大的经济损失。与新冠重症风险增加及死亡率升高相关的关键合并症包括心血管代谢紊乱,如1型和2型糖尿病(T1DM和T2DM)、动脉粥样硬化性心血管疾病、慢性肾脏病、高血压、心力衰竭和肥胖。即使在急性期过后症状仍持续存在,这被称为新冠后综合征。本研究旨在评估新冠后综合征与既往非糖尿病患者胰岛素抵抗发展之间的关系。对143例非糖尿病患者进行了一项前瞻性观察性研究,这些患者经PCR检测确诊为SARS-CoV-2感染阳性,并于2020年1月至2022年12月在我院住院。收集新冠感染后随访的入院0、4和12个月时的临床和辅助临床数据,并标记为t0、t4和t12。在静脉注射精氨酸刺激试验开始时及之后2、5、10和30分钟测量血糖、胰岛素和C肽水平。同样,计算BMI,并记录hs-CRP和ESR水平。对获得的结果进行统计学分析。超过三分之一(30.7%)的纳入患者出现了新冠后综合征。发现在我院住院的新冠后综合征患者中,75%在新冠急性感染后一年内发展为糖尿病;因此,可以说新冠后综合征的存在是代谢状态改变的主要风险因素,可导致糖尿病。在t0、t4和t12时间间隔比较血糖水平(106mg/dL)与BMI时,p值分别为0.214、0.042和0.058。发现BMI>30kg/m²的患者中,近62%在1年时血糖水平升高。同样,在此期间观察到胰岛素抵抗。与新冠急性感染相比,hsCRP的负相关系数为0.40,ESR的负相关系数为0.38。新冠后综合征与胰岛素抵抗之间的关联凸显了SARS-CoV-2感染的多样和广泛影响。应对新冠后综合征的复杂性需要一种全面的策略,该策略兼顾呼吸和代谢方面的考量,这对于提高那些忍受这种持续状况的人的健康至关重要。